Mesoblast (MESO) CFO awarded 650,000 options at A$2.90 strike, expiring 2032
Rhea-AI Filing Summary
Mesoblast Ltd reported that Chief Financial Officer James Michael O'Brien received a grant of 650,000 options to acquire Ordinary Shares. The options have an exercise price of A$2.90 per share, expire on December 22, 2032, and vest only if Mr. O'Brien achieves specified milestones.
Positive
- None.
Negative
- None.
Insights
CFO received performance-based options, a routine compensation grant.
Mesoblast Ltd granted CFO James Michael O'Brien 650,000 options with an exercise price of A$2.90 per share, expiring on December 22, 2032. The grant increases his potential equity exposure but does not involve open-market buying or selling.
The options vest only upon achievement of specified milestones, aligning part of his compensation with company and personal performance. Because this is a compensation award rather than a market transaction, it is generally viewed as neutral information for existing shareholders.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to buy) | 650,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. The exercise price for options is in Australian dollars.
- F2. Granted on December 23, 2025. Vesting is dependent on Mr. O'Brien achieving certain milestones
Key Figures
Key Terms
Option (Right to buy) financial
exercise price financial
vesting financial
FAQ
What equity award did Mesoblast (MESO) grant to its CFO?
What is the exercise price of the new Mesoblast (MESO) CFO options?
When do the Mesoblast (MESO) CFO options expire?
Are the Mesoblast (MESO) CFO options immediately vested?
How many Mesoblast (MESO) options does the CFO hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.